Another DPP-4 inhibitor, sitagliptin, has been shown to decrease LV cardiomyocyte Fpassive and enhance global LV performance due to elevated cGMP levels, PKG activity, and improved titin phosphorylation in a mouse model of obesity and DM [79]. This evidence concerns the gene PRKG1 and diabetes mellitus.